Table 2 Response characteristics.
Efficacy (95% CI) | |
|---|---|
Best overall response (all, n = 87) | 78% (68–86%) |
Complete response | 70% (59–79%) |
Partial response | 8% (3–16%) |
Progressive disease | 16% (9–26%) |
Could not be evaluated | 6% (2–13%) |
Ongoing response | 61% (44–75%) |
Best overall response (aggressive:DLBCL, PMBCL and tFL, n = 69) | 75% (64–85%) |
Complete response | 68% (56–79%) |
Partial response | 7% (2–16%) |
Progressive disease | 19% (10–30%) |
Could not be evaluated | 6% (2–14%) |
Best overall response (DLBCL, n = 58) | 78% (65–87%) |
Complete response | 71% (57–82%) |
Partial response | 7% (2–17%) |
Progressive disease | 21% (11–33%) |
Could not be evaluated | 2% (0–9%) |
Best overall response (FL, n = 13) | 92% (64–100%) |
Complete response | 77% (46–95%) |
Partial response | 15% (2–45%) |
Progressive disease | 8% (0–36%) |
Could not be evaluated | 0 |
Response of intent-to-treat (n = 92) | 74% (64–83%) |
Median duration of response, months (95% CI) | NR (23.4-NE) |
Median progression-free survival, months (95% CI) | 27.6 (11-NE) |
Median overall survival, months (95% CI) | NR (36.7-NE) |
